Catalyst Pharmaceuticals Inc (CPRX) to Post Q2 2019 Earnings of $0.03 Per Share, Piper Jaffray Companies Forecasts
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) – Investment analysts at Piper Jaffray Companies lifted their Q2 2019 earnings estimates for shares of Catalyst Pharmaceuticals in a note issued to investors on Monday, May 13th. Piper Jaffray Companies analyst J. Catanzaro now forecasts that the biopharmaceutical company will earn $0.03 per share for the quarter, up from their prior forecast of ($0.05). Piper Jaffray Companies also issued estimates for Catalyst Pharmaceuticals’ Q3 2019 earnings at $0.03 EPS, Q4 2019 earnings at $0.04 EPS and FY2019 earnings at $0.09 EPS.
Several other research analysts have also issued reports on the company. BidaskClub upgraded Catalyst Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, February 14th. Zacks Investment Research lowered Catalyst Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, February 13th. ValuEngine upgraded Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Monday, March 25th. Cantor Fitzgerald restated a “buy” rating and issued a $10.00 price target on shares of Catalyst Pharmaceuticals in a research report on Tuesday, March 19th. Finally, HC Wainwright set a $9.00 price target on Catalyst Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday. One equities research analyst has rated the stock with a sell rating and six have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $7.15.
Catalyst Pharmaceuticals (NASDAQ:CPRX) last announced its quarterly earnings data on Monday, May 13th. The biopharmaceutical company reported ($0.01) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.13) by $0.12. The firm had revenue of $12.45 million during the quarter, compared to the consensus estimate of $2.40 million. During the same quarter in the previous year, the business posted ($0.06) earnings per share.
Institutional investors have recently modified their holdings of the stock. Amalgamated Bank acquired a new stake in Catalyst Pharmaceuticals during the 4th quarter worth $28,000. Paloma Partners Management Co acquired a new stake in Catalyst Pharmaceuticals during the 4th quarter worth $30,000. Metropolitan Life Insurance Co. NY raised its stake in Catalyst Pharmaceuticals by 291.8% during the 4th quarter. Metropolitan Life Insurance Co. NY now owns 27,253 shares of the biopharmaceutical company’s stock worth $52,000 after buying an additional 20,297 shares during the period. Meeder Asset Management Inc. raised its stake in Catalyst Pharmaceuticals by 185.1% during the 4th quarter. Meeder Asset Management Inc. now owns 34,237 shares of the biopharmaceutical company’s stock worth $67,000 after buying an additional 22,227 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. raised its stake in Catalyst Pharmaceuticals by 18.3% during the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 36,700 shares of the biopharmaceutical company’s stock worth $70,000 after buying an additional 5,688 shares during the period. 47.85% of the stock is currently owned by institutional investors and hedge funds.
Catalyst Pharmaceuticals Company Profile
Catalyst Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with lambert-eaton myasthenic syndrome in the United States.
See Also: What is the 52-week high/low?
Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.